Our team
Co-Founder, Chief Executive Officer
David is responsible for the scientific development and implementation of Gatehouse Bio’s technology platform.
Prior to co-founding Gatehouse Bio, David was the Head of Radiogenomics at MiraDx, where he led the development of commercial diagnostics for radiation and immunotherapy response. As a scientist, David designed and implemented the PK/PD and biomarker strategy to support Biogen’s antisense oligo therapeutic pipeline. David created gold standard R&D tools, including the first two anti-DICER mAbs, and pioneering the dual-luciferase assay platform used to measure small RNA function that have been used in >50,000 publications. He also contributed seminal discoveries to the field regarding small RNA biogenesis and characterizing RISC activity.
David earned a PhD in molecular biology from the University of Connecticut and completed a postgraduate fellowship in radiation oncology and molecular genetics at the Yale University School of Medicine
Co-Founder, Chief Business Officer
Neal is responsible for establishing the business strategy, commercial framework and software execution for the company.
Prior to co-founding Gatehouse Bio, Neal held executive leadership roles in Fortune 500 companies (NYSE: MSI, DELL, VMW, and NASDAQ: CMCSA), managing execution and sales for organizations focused on data-driven systems and software platforms. As a serial intrapreneur, Neal has started new businesses within large organizations, and has led the technical diligence for mergers and acquisitions over $1B in value. Neal’s experience in building large scale ecosystems and complex commercial collaborations has led to creative partnerships that continue to drive growth within these companies.
Neal earned an MBA from the Wharton School of Business and a BS in computer and electrical engineering from Rutgers University. He earned dual certificates in Computational Biology and Precision Medicine from the Harvard Medical School. Neal holds 10 patents covering software architecture and complex data system design.
Drug Development
Johnny is responsible for designing the oligonucleotide screening platform, hit-to-lead validation, and PK/PD assay development.
Prior to joining Gatehouse Bio, Johnny was a senior scientist at Alltrna on the cell biology and discovery screening team, where he developed a high throughput oligonucleotide screening platform for tRNA function, toxicity, and stability. He also established the standard cell on-boarding procedures and all cell-based assays. As an Investigator at Novartis (NIBR), he managed preclinical R&D to develop and characterize novel GEMMs using CRISPR/Cas9 technology.
Johnny earned a PhD in Cell and Developmental Biology from SUNY Upstate Medical University. He completed a postgraduate fellowship at the John’s Hopkins University School of Medicine in Cellular and Molecular Biology.
Drug Discovery
Molly is responsible for early-stage discovery, and establishing Gatehouse Bio’s hit-to-lead funnel using small RNA sequencing data from patient samples.
Prior to joining Gatehouse Bio, Molly was a Data Scientist at Aetna where she led analytic development of clinical marketing campaigns promoting healthy behavior changes through targeted interventions that leveraged supervised and unsupervised predictive modeling. Molly also implemented analytic solutions to support beta testing of healthcare products intended to provide personalized care plans for patients with chronic conditions.
Molly earned an MS in Analytics from Northwestern University, and a BS in Mathematics from Saint Olaf College.
Drug Discovery
Christian is responsible for designing and implementing the bioinformatics analysis pipeline at Gatehouse Bio, as well as in silico lead validation and modeling.
Prior to joining Gatehouse Bio, Christian was a Research Scientist at the Harvard Medical School where he established and optimized an integrated wet-lab and dry-lab pipeline for NET-seq for RNA Polymerase II footprinting.
Christian earned a PhD in Genetics from Montpellier SupAgro. He completed a postgraduate fellowship at the University of Minnesota and University of Strasbourg designing and implementing multi-omics bioinformatics tools for early-stage discovery and R&D of mRNA and protein expression.
Drug Discovery
Matt is responsible for early-discovery and development of Gatehouse Bio’s technology platform.
Prior to Gatehouse Bio, Matt was a database engineer at Epic Hosting on the data analytics and administration team, where he developed automated systems and pipelines for SQL management and analytics workflows at multiple hospital systems.
Matt holds a PhD in chemical engineering from the University of Wisconsin-Madison. His dissertation work was on the development and application of methods for incorporating multi-omics data into genome-scale constraint-based metabolic models. He also holds an MS and BS in chemical engineering from the Pennsylvania State University.
Data Engineering
Sara is responsible for pipeline automation and optimize of Gatehouse Bio’s analytical pipeline, and supports the ETL database for laboratory science, data science, and analytics teams.
Prior to Gatehouse Bio, Sara worked as a senior data engineer at Iora Health on the business clinical intelligence team, where she built key features of the company's electronic health record, managed clinical data products, and developed ETL to support financial, clinical, and operational data science and analytics.
Sara earned a BS from Dartmouth College in Quantitative Social Science and Global Health. Sara completed Post Baccalaureate studies at the Harvard Extension School in Biology and Chemistry
Data Engineering
Nathan is responsible for architecting Gatehouse Bio’s database and software applications for small RNA featurization and analysis. He brings 20 years of experience in software engineering, with a strong focus on efficient and reliable signal extraction from large, noisy datasets, including computer vision, web analytics, tracking objects through multisource data fusion, and natural language search.
Prior to Gatehouse Bio, Nathan was vice president of technology at Textaurant,serving as the lead developer and engineering manager producing a data management platform. After less than 5 years from development-to-sales, the company was acquired. Most recently, Nathan improved the reliability and efficiency of TripAdvisor’s search tools, reducing run times by a factor of 10,000, memory requirements by a factor of 10, and improving search accuracy.
Nathan holds a BS in computer science from Worcester Polytechnic Institute.
Drug Development
Jessie works on Gatehouse Bio's discovery validation and therapeutic oligonucleotide screening platform to establish and identify lead drugs for pre-clinical and clinical research.
Prior to Gatehouse Bio, Jessie was a research technician at the Hanna Lab at Brigham and Women's Hospital. She worked on elucidating cross-talks between the UPR pathway and other pathways in S. Cerevisiae, which involved experimental design and expertise in many molecular biology techniques.
Jessie holds a BS in Biology from Brandeis University. Her senior thesis with the Haber Lab contributed to the discovery of the Genotoxin-induced Targeted Autophagy pathway.
Drug Development
Anastasia is responsible for validation of small RNA disease models and biomarker assay development in support of Gatehouse Bio’s R&D pipeline. The scope of her work includes design and optimization of high-throughput RT-qPCR assays and the R&D activity to establish a link between sequencing and RT-qPCR data.
Prior to joining Gatehouse Bio, Anastasia was a Postdoctoral Fellow at the Baylor College of Medicine where she studied molecular pathways regulating host-microbiome interactions using C. elegans as a model organism.
Anastasia earned a PhD in Forensic Genetics from Flinders University of South Australia. Her dissertation work focused on the development of reliable discrimination of forensically relevant soil samples using metagenomic profiling of soil biota. She earned an MS and BS in Cell and Molecular Biology from Moscow State University of Fine Chemical Technologies.
Chief Operating Officer
Prior to joining Gatehouse Bio, Alan was the Director of Technology at Gee Partners and led projects for product testing, development, feasibility and commercialization in the high-tech space. Additionally, he supported strategic business initiatives, playing a key role in the acquisition and restructuring of RadioShack, which lead to the subsequent formation of General Wireless Operations dba RadioShack.
Earlier in his career, Alan served as the senior product development architect at Dell and was the director of 3GSM global portfolio management, the director of product operations for Europe, Middle East, and Africa, the director of engineering for CDMA performance category mobile phone development, and director of CDMA system and field testing. Prior to that, he was the lead engineering manager at Bell Laboratories for over 20 years, where he worked on breakthrough innovations and technologies such as high-speed cable, satellite transmission systems, wireless infrastructure, fiber-to-the-home, loop plant electronics, and wired products.
Alan holds a PhD in applied mechanics and mathematics, an MS in applied mechanics, and a BS in aerospace engineering from the NYU Polytechnic School of Engineering. He also holds a black belt in Six Sigma process management.
Business Development
Sean manages early-stage commercial opportunities for Gatehouse Bio and supports senior management in forming collaborations with industry and academic partners. Sean also leads competitive intelligence and due diligence while working with senior management to execute business strategy.
Prior to Gatehouse Bio, Sean worked as a business development analyst at Neurocentrx Pharma, a specialty pharmaceutical company focused on neurology, and as a business development intern at Vasorum, a cardiovascular medical device company.
Sean holds an MSc in biotechnology and business from the UCD Michael Smurfit Graduate School of Business and a BSc in biochemistry and microbiology from the National University of Ireland, Galway. He is currently studying precision medicine at the Harvard Medical School.
Our scientific advisors
